“US mRNA specialist Moderna (Nasdaq: MRNA) saw its shares close up 9.3% at $111.08 on Monday after the announcement of a collaboration agreement to investigate Shanghai, China-based CARsgen Therapeutics’ (2171: HK) investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.

CT041 (satricabtagene autoleucel), is CARsgen’s autologous CAR T-cell product being…”

Continue reading at the original source, linked here.